Vivek Subbiah: Redefining pancreatic cancer management with tumor-agnostic precision medicine
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared his recent article on X:
“Redefining pancreatic cancer management with tumor-agnostic precision medicine.”
Title: Redefining pancreatic cancer management with tumor-agnostic precision medicine
Authors: Neha K Reddy and Vivek Subbiah
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
More posts featuring Vivek Subbiah.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023